|
Sep 30
|
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
|
|
Sep 12
|
Innate Pharma Reports First Half 2024 Business Update and Financial Results
|
|
Sep 9
|
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
|
|
Jul 25
|
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
|
Jan 12
|
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
|
|
Jan 4
|
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
|
|
Jan 4
|
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
|
|
Jan 4
|
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
|
|
Dec 19
|
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
|
|
Dec 18
|
Innate Pharma Announces Leadership Change
|
|
Dec 11
|
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
|
|
Dec 10
|
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
|
|
Nov 27
|
Innate Pharma to Host Virtual KOL Event on Lacutamab
|
|
Nov 7
|
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
|
|
Nov 3
|
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
|
|
May 26
|
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
|
|
May 15
|
Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
|